Table 5 Novel agents in R/R DLBCLs

Single agent

venetoclax

BCL2

ORR/CRR, 17.6% (6/34)/11.8% (4/34)

NA

Ibrutinib

BTK

ORR/CRR, 25% (20/80)/10% (8/80)

ABC DLBCL: ORR/CRR, 37% (14/38)/16% (6/38)

GCB DLBCL: ORR/CRR, 5% (1/20)/5% (1/20)

Zanubrutinib

BTK

ORR/CRR, 29.3% (12/41)/17.1% (7/41)

ABC DLBCL: ORR/CRR, 36% (9/25)/24% (6/25)

GCB DLBCL: ORR/CRR, 25% (1/4)/25% (1/4)

Copanlisib

PI3Kα/δ

ORR/CRR, 19.4% (13/67)/7.5% (5/67)

ABC DLBCL: ORR/CRR, 31.6% (6/19)/21.1% (4/19)

GCB DLBCL: ORR/CRR, 13.3% (4/30)/3.3% (1/30)

Parsaclisib

PI3Kδ

ORR/CRR, 25% (15/60)/15% (9/60)

BTK inhibitor naïve: ORR/CRR, 25.5% (14/55)/14.5% (8/55)

BTK inhibitor experienced: ORR/CRR, 20% (1/5)/20% (1/5)

Temsirolimus

mTORC1

ORR/CRR, 28.1% (9/32)/12.5% (4/32)

NA

Tazemetostat

EZH2

EZH2 mutations: ORR/CRR, 40% (4/10)

EZH2 unmutated: ORR/CRR, 17.6% (15/85)

NA

Abexinostat

Pan-HDAC

ORR/CRR, 31.3% (5/16)/6.3% (1/16)

Mocetinostat

HDAC 1–3, 11

ORR/CRR (110 mg), 26.3% (5/19)/5.3% (1/19)

Total ORR/CRR, 18.9% (7/37)/2.7% (1/19)

Trotabresib

BET

ORR/CRR, 13.0% (3/23)/8.7% (2/23)

Lenalidomide

IMiDs

ORR/CRR, 27.5% (11/40)15.0 (6/40)

Non-GCB DLBCL: ORR/CRR, 52.9% (9/17)/29.4% (5/17)

GCB DLBCL: ORR/CRR, 4.3% (1/23)/4.3% (1/23)

Lenalidomide

IMiDs

ORR/CRR, 27.5% (14/51)/9.8% (5/51)

Non-GCB DLBCL: ORR/CRR, 28.6% (8/28)/14.3% (4/28)

GCB DLBCL: ORR/CRR, 26.1% (6/23)/4.3% (1/23)

ABC DLBCL: ORR/CRR, 45.5% (5/11)/27.3% (3/11)

GCB DLBCL: ORR/CRR, 21.4% (3/14)/7.1% (1/14)

Selinexor

XPO1

ORR/CRR, 28.3% (36/127)/11.8% (15/127)

High/ low Myc protein expression: ORR, 13% (6/47)/42% (22/52)

DEL/non-DEL: ORR, 9.7% (3/31)/40.3% (23/57)

Combination

Ven-OLI

ORR/CRR, 55.6% (15/27)/37.0% (10/27)

Non-GCB DLBCL: ORR/CRR, 61.5% (8/13)/53.8% (7/13)

GCB DLBCL: ORR/CRR, 50.0% (7/14)/21.4% (3/14)

CUDC-907-R

ORR/CRR, 63.6% (7/11)/18% (2/11)

MYC non-altered: ORR/CRR, 71.4% (5/7)/ 0% (0/7)

MYC-altered: ORR/CRR, 50% (2/4)/50% (2/4)

iR2

ORR/CRR, 49.4% (42/85)/28.2% (24/85)

ABC DLBCL: ORR/CRR, 54.8% (17/31)/32.3% (10/31)

GCB DLBCL: ORR/CRR, 35.7% (5/14)/14.3% (2/14)

Temsirolimus-Len

ORR/CRR, 25.6% (10/39)/12.8% (5/39)

Cases of CR: 2 cases of ABC DLBCL, 2 cases of GCB